AVR anteristech.com: Quick Liquidity

Anteris Technologies Global (AVR) develops advanced cardiac prostheses, the demand for which in cardiac centers is driven by the products' exceptional physical characteristics. The company's financial stability relies on the supply of implants to medical institutions for the therapy of severe pathologies. The current figure is 14.59. The price trend reflected below complements data on the implementation of various surgical approaches, which minimizes bureaucratic complexities when bringing products to market.

The high margins of DurAVR bioprostheses create a solid foundation for cash generation at Anteris Technologies Global (AVR). This ratio assesses solvency by considering only cash and accounts receivable while completely excluding inventory. This allows investors to determine the company's ability to instantaneously settle short-term liabilities without selling products. By analyzing the critical liquidity trend, one can evaluate the balance between financial security and capital efficiency.